Abstract
Giant cell tumor of bone (GCTB) is a rare benign primary tumor of the bone. Bisphosphonate therapy is curently used in GCTB because of its anti-osteoclastic effects. Denosumab is fully human monoclonal antibody that inhibit disease progression in metastatic GCTB. We summurized tree patients GCTB patients with lung metastasis. The patient were received between 12-18 months denosumab and remain without disease progression between 6-15 months after discontinuous of treatment. Due to the indolent nature of the tumor follow-up period may be short, however we thinks it is an important experience fort his condition
References
- Dominkus M, Ruggieri P,Bertoni F, et al. Histologically verified lung metastases in benign giant cell tumours-14 casesfrom single institution. Int Orthop 2006;30:499-504
- Viswanathan S, Jambhekar NA. Metastatic giant cell tumor of bone: are there associated factorsand best treatment modalities? Clin Orthop Relat Res 2010;468:827-33
- McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am 1986;68:235-4
- Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumorof the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 2010;36:1-7
- Bhatia S, Miszczyk L, Roelants M, et al. Radiotherapy for marginally resected , unresectable or recurrent giant cell tumor of the bone: a rare cancer network study. Rare Tumors 2011;3:e48
- Siebenrock KA, Unni KK, Rock MG. Giant-cell tumour of bone metastasising to the lungs. A long- term follow-up. J Bone Joint Surg Br 1998;80:43-7
- Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-80
- Balke M, Campanacci L, Gebert C, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 2010;10:462
Abstract
Dev hücreli kemik tümörü ( DHKT) nadir görülen benign bir primer kemik tümörüdür. Günümüzde anti osteoklastik aktiviteye sahip bifosfanat tedavisi kullanılmaktadır. Denosumab tamamen insan kaynaklı monoklonal antikordur ve metastatik DHKT'de hastalık progresyonunu inhibe eder. Akciğer metastazı olan 3 DHKT'lü hastayı özetledik. Hastalar 12 ile 18 ay arasında denosumab kullanmışlardı. Tedavi kesilmesinde sonraki 6 ile 15 aylık takipte hastalık progresyonu görülmedi. Hastalık yavaş seyirli olması nedeniyle takip süermiz kısa olabilir ancak bu konuda önemli bir deneyim olduğunu düşünmekteyiz.
References
- Dominkus M, Ruggieri P,Bertoni F, et al. Histologically verified lung metastases in benign giant cell tumours-14 casesfrom single institution. Int Orthop 2006;30:499-504
- Viswanathan S, Jambhekar NA. Metastatic giant cell tumor of bone: are there associated factorsand best treatment modalities? Clin Orthop Relat Res 2010;468:827-33
- McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am 1986;68:235-4
- Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumorof the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 2010;36:1-7
- Bhatia S, Miszczyk L, Roelants M, et al. Radiotherapy for marginally resected , unresectable or recurrent giant cell tumor of the bone: a rare cancer network study. Rare Tumors 2011;3:e48
- Siebenrock KA, Unni KK, Rock MG. Giant-cell tumour of bone metastasising to the lungs. A long- term follow-up. J Bone Joint Surg Br 1998;80:43-7
- Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-80
- Balke M, Campanacci L, Gebert C, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 2010;10:462
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | December 1, 2014 |
| Published in Issue | Year 2014 Volume: 47 Issue: 3 |